On Thursday, Novavax Inc (NASDAQ:NVAX) reported fourth-quarter 2024 sales of $88.31 million, compared to $291 million a year, beating the consensus of $84.35 million. The decrease was due to lower product sales under APA agreements.
The COVID-19 vaccine maker reported an earning loss of 51 cents per share, down from $1.44 a year ago, in line with the Wall Street Estimate.
Also Read: Wegovy Maker Novo Nordisk To Buy Novavax’s Czech Republic Manufacturing Facility For $200 Million
“In 2024, we unveiled our new corporate growth strategy, shifting our focus from commercializing our COVID-19 vaccine to maximizing the value of our cutting-edge technology platform through pipeline expansion and partnerships for our development-stage vaccine candidates and our Matrix-M adjuvant,” said John C. Jacobs, President and Chief Executive Officer, Novavax. “As we look to 2025 and beyond, we believe we are well positioned to potentially create significant value for all stakeholders.”
Nuvaxovid sales reached $49.8 million, down from $251.5 million a year ago. The company ended 2024 with over $1 billion in cash and accounts receivables.
Novavax has transitioned the lead commercial responsibility of Nuvaxovid to Sanofi SA (NASDAQ:SNY) for select markets beginning with the 2025-2026 vaccination season.
Since Novavax is reliant on Sanofi’s sales forecasts for certain revenue components, these will not be included in the 2025 Revenue Framework at this time.
Novavax expects to achieve adjusted licensing, royalties, and other revenue of between $300 million and $350 million in 2025. Novavax is eligible to receive royalties in the high teens to low twenties percent on Sanofi sales.
Equity research can be a valuable source of information for learning about a company's fundamentals. Analysts create financial models based on the fundamentals and expected future earnings of a company to arrive at a price target and recommendation for the stock.
Shares of Novavax have an average 1-year price target of $19.0, representing an expected upside of 141.41%.
Because of differences in assumptions, analysts can arrive at very different price targets and recommendations. No analysts have bearish recommendations on Novavax, while 1 analysts have bullish ratings. The street high price target from HC Wainwright & Co. is $19.0, while the street low from HC Wainwright & Co. is $19.0.
Price Action: NVAX stock is up 10.4% at $8.08 at the last check Thursday.
Photo via Shutterstock
Read Next:
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。